SCHEMBL558116

SCHEMBL558116

CC(C)(C)OC(=O)CCCCCCCCCCCCCCCCC(=O)N(CCC(=O)OC(C)(C)C)CC(=O)OCc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 2/20 0.42
L3MBTL1 Q9Y468 5/20 0.42
ALDH1A1 P00352 2/20 0.40
MAPK1 P28482 1/20 0.40
KDM4A O75164 1/20 0.38
KDM5A P29375 1/20 0.38
KDM4C Q9H3R0 1/20 0.38
PHF8 Q9UPP1 1/20 0.38
KDM2A Q9Y2K7 1/20 0.38
LMNA P02545 1/20 0.38
SYK P43405 1/20 0.37
CTSL P07711 1/20 0.37
CTSB P07858 1/20 0.37
CTSS P25774 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
EPHX2 P34913 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16620311 0.89 ALOX5 (0.46) ALOX5L3MBTL1ALDH1A1MAPK1LMNA
SCHEMBL3903941 0.86 L3MBTL1 (0.45) L3MBTL1ALDH1A1MAPK1LMNASYK
SCHEMBL15194354 0.83 ALOX5 (0.43) ALOX5L3MBTL1ALDH1A1MAPK1LMNA
SCHEMBL22481266 0.83 ALDH1A1 (0.53) L3MBTL1ALDH1A1MAPK1LMNASYK
SCHEMBL25209279 0.82 L3MBTL1 (0.40) L3MBTL1ALDH1A1MAPK1LMNASYK
SCHEMBL20089220 0.81 L3MBTL1 (0.46) L3MBTL1ALDH1A1MAPK1LMNASYK
SCHEMBL3914953 0.81 ALOX5 (0.46) ALOX5L3MBTL1ALDH1A1MAPK1LMNA
SCHEMBL1569283 0.80 ALDH1A1 (0.43) L3MBTL1ALDH1A1MAPK1LMNASYK
SCHEMBL12990128 0.80 ALDH1A1 (0.53) L3MBTL1ALDH1A1MAPK1LMNASYK
SCHEMBL3664799 0.80 MEN1 (0.43) L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE46170-E1 Insulin derivatives NOVO NORDISK A/S (DK) 2016-10-04 US disclosed
EP-2256130-B1 Novel insulin derivatives NOVO NORDISK AS (DK) 2013-09-25 EP disclosed
US-8476228-B2 Insulin derivatives NOVO NORDISK A/S (DK) 2013-07-02 US disclosed
EP-1846446-B1 INSULIN DERIVATIVES NOVO NORDISK AS (DK) 2013-06-26 EP disclosed
US-20120035104-A1 Insulin derivatives NOVO NORDISK A/S (DK) 2012-02-09 US disclosed
US-8067362-B2 Antidiabetic agents; genetic engineered polypeptide; having a side chain attached alpha -amino group of the N-terminal amino acid of the B chain via an amide bond, with free carboxylic acid group, a fatty acid; soluble at physiological pH, prolonged profile of action; hypoglycemic agents NOVO NORDISK AS (DK) 2011-11-29 US disclosed
EP-2256130-A1 Novel insulin derivatives Novo Nordisk A/S (DK) 2010-12-01 EP disclosed
US-20080076705-A1 Insulin Derivatives NOVO NORDISK A/S (DK) 2008-03-27 US disclosed
EP-1846446-A1 INSULIN DERIVATIVES NOVO NORDISK A/S (DK) 2007-10-24 EP disclosed
WO-2006082204-A1 INSULIN DERIVATIVES NOVO NORDISK A/S (DK) 2006-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035104-A1 Insulin derivatives IAPP, INSR, GPR119 ALOX5 2043/4885L3MBTL1 2602/4885ALDH1A1 4358/4885
US-20080076705-A1 Insulin Derivatives IAPP, INSR, GPR119 ALOX5 1990/4885L3MBTL1 2330/4885ALDH1A1 4511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.